Dr. Sanaz Memarzadeh, MD

Dr. Memarzadeh practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Memarzadeh's NPI, 1518998244, was assigned on July 5, 2006. Dr. Memarzadeh graduated from University of Pittsburgh School of Medicine in 1996. Dr. Memarzadeh holds California license A65689.

Dr. Memarzadeh's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Memarzadeh's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Memarzadeh is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Health Westwood OBGYN. Dmand AI also links Dr. Memarzadeh to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Memarzadeh practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Memarzadeh's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Memarzadeh is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dr. Memarzadeh is licensed in California.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Memarzadeh treats.

CMS data shows 278 Medicare services from Dr. Memarzadeh across 4 procedure codes in 2024, all of them office visits, for 165 Medicare patients. Medicare paid $27,581 for them. Every service was in an office.

CMS counts 165 Medicare patients who saw Dr. Memarzadeh in 2024. The largest group is 65 to 74, with 82 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.45, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Memarzadeh's median patient age at 63, with 99% women.

In 2024, Dr. Memarzadeh wrote 36 Medicare Part D claims for 22 patients. 81% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $825 in total drug cost. In 2022, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Memarzadeh for performance year 2024, reported as part of a group. CMS lists Dr. Memarzadeh as offering telehealth.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 24 papers to Dr. Memarzadeh, published from 2002 to 2025. 2021 was the busiest year, with 3. The most frequent topics are Ovarian Neoplasms, Disease Models, Animal and Mice, Inbred C57BL. Dr. Memarzadeh has published most often in Proc Natl Acad Sci U S A. Dr. Memarzadeh's most frequent co-authors are Daniel Young Paik, MD, Jonathan Samuel Berek, MD and Jiaoti Huang, MD, PhD.

Dmand AI links Dr. Memarzadeh to 3 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Ovarian Epithelial, Ovarian Neoplasms and Pathologic Complete Response.

CMS Open Payments shows 2 general payments to Dr. Memarzadeh from 2 drug and device companies from 2016 to 2020. Consulting fees make up the largest share, 98% of the total. Clovis Oncology, Inc. paid the most, $1,700.

Dmand AI lists 8 awards for Dr. Memarzadeh, most recently Super Doctors of Southern California in 2024. Dr. Memarzadeh serves on National Institute of Health Mechanisms of Cancer Therapeutics A Study Section.

Dr. Memarzadeh graduated from University of Pittsburgh School of Medicine in 1996. Dr. Memarzadeh is a member of ACS, American Gynecological & Obstetrical Society, ASCO and Society of Gynecologic Oncology.

Dr. Memarzadeh is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.